drugset / Trial / NCT00893217

BEYOND Pilot Study

NCT00893217

Phase 2 Completed 71 enrolled Bayer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to valuate safety and tolerability of Betaseron.

Timeline

Start
2002-11
Primary completion
Completion
2003-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Interferon beta-1b Protein / enzyme biologic 250 ug Subcutaneous
Subject Interferon beta-1b Protein / enzyme biologic 500 ug Subcutaneous